SCHEMBL5284933

SCHEMBL5284933

CCC(NCC(=O)O)S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.43
MMP12 P39900 4/20 0.43
MMP7 P09237 3/20 0.43
MMP13 P45452 3/20 0.43
ACE P12821 2/20 0.43
ATM Q13315 1/20 0.43
GAA P10253 1/20 0.41
HSD11B1 P28845 1/20 0.40
PSIP1 O75475 1/20 0.40
KCNA5 P22460 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.38
FPR1 P21462 1/20 0.38
LMNA P02545 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20556306 0.80 ATM (0.51) MMP1MMP12MMP7MMP13ACE
SCHEMBL5295498 0.75 HSD11B1 (0.46) MMP1MMP12MMP7MMP13ACE
SCHEMBL28801398 0.73 MME (0.35) ACEMAPTLMNACA1CA2
SCHEMBL5858109 0.72 MMP1 (0.43) MMP1MMP12MMP7MMP13ACE
Oxalic Acid SCHEMBL8057905 0.72 KDM4E (0.53) KMT2ALMNA
SCHEMBL26478541 0.72 ATM (0.50) MMP13ATMMAPTCA12CA1
SCHEMBL1700880 0.70 MMP2 (0.50) MMP1MMP12MMP7MMP13ACE
SCHEMBL8778753 0.70 PSIP1 (0.50) MMP1MMP12MMP7MMP13ACE
Hydrochloric Acid SCHEMBL5120935 0.69 MMP2 (0.49) MMP1MMP12MMP7MMP13ACE
SCHEMBL3177566 0.69 LMNA (0.51) ATMKCNA5KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 MMP1 3485/4885MMP12 1035/4885MMP7 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.